Key facts
- GRIT Biotechnology’s last known valuation is $291.3M (Oct 2025).
- It has raised $124.2M; the latest was Later Stage VC ($53.3M) in Oct 2025.
- Notable investors include GL Ventures, CICC Capital, B Capital Group, Green Pine Capital Partners, Qianhai FoF — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for GRIT Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for GRIT Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GRIT Biotechnology
Developer of immunotherapy intended to cure solid tumors. The company develops and researches Tumor Infiltration Lymphocytes (TIL) immunotherapy for solid tumors, committing to improving the treatment of tumors.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 130
- Website
- grit-bio.com/
- Ownership
- Privately Held (backing)
GRIT Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GRIT Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GRIT Biotechnology in its N-PORT filings yet. We sweep new filings monthly.